Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05911841 · ClinicalTrials.gov registry record · Phase 2
A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis
A Phase 2 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 2
- Development phase
- 234
- Enrollment target
NCT05911841 is a Phase 2 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 234 participants.
The verdict
NCT05911841, a Phase 2 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 234 participants
- Enrollment target
Study Summary
The main purpose of this study is to describe the efficacy and safety of LY3454738 in adult participants with moderate-to-severe atopic dermatitis (AD).
Interventions
- DRUG Placebo
- DRUG LY3454738
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 234 participants |
| Start Date | 2023-06-21 |
| Est. Completion | 2025-03-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05911841
The ClinicalTrials.gov registry entry for NCT05911841 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 234 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05911841 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05911841 about?
NCT05911841 is a clinical study titled "A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis". The main purpose of this study is to describe the efficacy and safety of LY3454738 in adult participants with moderate-to-severe atopic dermatitis (AD).
What is the current status of trial NCT05911841?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 234 participants. The study started on 2023-06-21. Estimated completion is 2025-03-14.
What interventions are being tested in trial NCT05911841?
The interventions under investigation include: Placebo (DRUG), LY3454738 (DRUG).
Who is sponsoring clinical trial NCT05911841?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.